ARCH ready for big bets with new $400m venture fund
This article was originally published in Scrip
Executive Summary
ARCH Venture Partners raised $400m for its eighth venture capital fund of which 50% to 75% is likely to be invested in biotechnology, including contributions to one or two big ideas for groundbreaking therapeutic platforms or other compelling opportunities.